Ira T Lott1, Kathryn Osann, Eric Doran, Linda Nelson. 1. Department of Pediatrics, University of California, Irvine Medical Center, 101 The City Dr S, Bldg 2, Third Floor, Orange, CA 92868-4482, USA. Itlott@uci.edu
Abstract
BACKGROUND: Individuals with Down syndrome who develop Alzheimer disease may show an improvement in cognitive functioning after treatment with acetylcholinesterase inhibitors. OBJECTIVE: To determine whether individuals with Down syndrome and Alzheimer disease will show improvement after institution of donepezil treatment. DESIGN: A nonrandomized controlled trial using donepezil in a pilot study format. SETTING: Academic medical center. PATIENTS: Convenience sample of 6 treated patients with Down syndrome and 9 closely matched historical control subjects. INTERVENTION: Oral administration of donepezil for a 5-month period. PRIMARY OUTCOME MEASURE: The Down Syndrome Dementia Scale. RESULTS: Significant improvement in dementia scores for the treated group during a 3- to 5-month period (P =.03). CONCLUSIONS: Acetylcholinesterase inhibitors may be helpful in reversing the symptoms of dementia during early and middle stages of cognitive decline. These findings support the rationale for a more extensive study of the efficacy of acetylcholinesterase inhibitors in Down syndrome dementia.
BACKGROUND: Individuals with Down syndrome who develop Alzheimer disease may show an improvement in cognitive functioning after treatment with acetylcholinesterase inhibitors. OBJECTIVE: To determine whether individuals with Down syndrome and Alzheimer disease will show improvement after institution of donepezil treatment. DESIGN: A nonrandomized controlled trial using donepezil in a pilot study format. SETTING: Academic medical center. PATIENTS: Convenience sample of 6 treated patients with Down syndrome and 9 closely matched historical control subjects. INTERVENTION: Oral administration of donepezil for a 5-month period. PRIMARY OUTCOME MEASURE: The Down Syndrome Dementia Scale. RESULTS: Significant improvement in dementia scores for the treated group during a 3- to 5-month period (P =.03). CONCLUSIONS:Acetylcholinesterase inhibitors may be helpful in reversing the symptoms of dementia during early and middle stages of cognitive decline. These findings support the rationale for a more extensive study of the efficacy of acetylcholinesterase inhibitors in Down syndrome dementia.
Authors: Christy M Kelley; Brian E Powers; Ramon Velazquez; Jessica A Ash; Stephen D Ginsberg; Barbara J Strupp; Elliott J Mufson Journal: J Comp Neurol Date: 2014-04-15 Impact factor: 3.215
Authors: Jonathan D Santoro; Dania Pagarkar; Duong T Chu; Mattia Rosso; Kelli C Paulsen; Pat Levitt; Michael S Rafii Journal: J Neurol Date: 2020-09-12 Impact factor: 6.682